(lp0
S'Epizyme Inc.  Breaks into New 52-Week High on March 28 Session Equities.com - 10 hours ago Shares of Epizyme Inc.  broke into a new 52-week high yesterday, hitting a peak of $17.80. Shares closed at $17.40 after opening at $17.70 for a move of -1.14%.Epizyme Inc  Issues Earnings Results, Beats Expectations By $0.05 EPS - Chaffey BreezeEpizyme Inc  Given Consensus Rating of Buy by Brokerages - Sports Perspectives'
p1
aS'Epizyme Earns $6 Million Milestone Payment from GlaxoSmithKline for Initiation ... GlobeNewswire  - Sep 15, 2016 CAMBRIDGE, Mass., Sept. 15, 2016  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced it has earned a $6 million milestone payment from&nbsp;...'
p2
aS'Epizyme Elects Kevin Conroy to its Board of Directors GlobeNewswire  - Feb 7, 2017 CAMBRIDGE, Mass., Feb. 07, 2017  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company has elected industry veteran Kevin Conroy,&nbsp;...'
p3
aS'Epizyme Announces Presentation at JP Morgan 35th Annual Healthcare Conference GlobeNewswire  - Jan 3, 2017 CAMBRIDGE, Mass., Jan. 03, 2017  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that Robert Bazemore, chief executive officer of Epizyme, will&nbsp;...'
p4
aS'Epizyme Establishes Collaboration with Foundation Medicine to Support ... GlobeNewswire  - Sep 21, 2016 CAMBRIDGE, Mass., Sept. 21, 2016  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced that the Company has entered into a collaboration agreement&nbsp;...'
p5
aS'Epizyme Appoints Pamela Strode as Vice President, Regulatory Affairs and ... GlobeNewswire  - Sep 29, 2016 CAMBRIDGE, Mass., Sept. 29, 2016  -- Epizyme, Inc. , a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has appointed Pamela Strode to the&nbsp;...'
p6
aS'Epizyme President of Research and Chief Scientific Officer, Robert Copeland ... GlobeNewswire  - Mar 9, 2017 CAMBRIDGE, Mass., March 09, 2017  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that President of Research and Chief Scientific Officer, Robert&nbsp;...Epizyme  Reports A Narrower Q4 Loss - Yahoo FinanceEpizyme Inc.  Breaks into New 52-Week High on March 09 Session - Equities.com'
p7
aS"Epizyme Provides Update on Execution of Clinical Program and Reports Third ... GlobeNewswire  - Nov 3, 2016 CAMBRIDGE, Mass., Nov. 03, 2016  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today recapped recent progress of the Company's clinical-stage programs and&nbsp;..."
p8
aS'Epizyme President of Research and Chief Scientific Officer Named AAAS Fellow GlobeNewswire  - Nov 21, 2016 21, 2016  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that President of Research and Chief Scientific Officer, Robert A. Copeland, Ph.'
p9
aS'Epizyme Inc Risk Points versus Health Care CML News - Mar 24, 2017 This is a scatter plot analysis of the critical risk points from the option market for Epizyme Inc  compared to its own past and the Health Care ETF.'
p10
a.